Nucleation-Controlled Ostwald Ripening with Polymer Inhibition Predicts ASD Phase Evolution Trajectories

Borrowed from volcano science, a new theory predicts how drugs stay dissolved — or crystallize out — in the gut.

Volcanic glass dissolution kinetics
Competitive nucleation-growth with selective polymer crystallization inhibiti...
Pharmaceutical amorphous solid dispersion dissolution
7Composite
5Confidence
7Groundedness
Share:XLinkedIn

When a drug is swallowed, it needs to dissolve in the gut to enter the bloodstream. But many modern drugs are finicky — they don't dissolve well in their normal crystalline form, so pharmaceutical scientists mix them with polymers (long-chain molecules, like a souped-up plastic) to keep them in an amorphous, or disordered, state. Think of it like keeping sugar dissolved in warm tea instead of letting it crystallize on the bottom. The challenge is that this disordered state is unstable — the drug wants to crystallize, which makes it less effective. Understanding exactly how and when crystallization happens is a major unsolved problem in drug delivery. This hypothesis borrows a framework from a seemingly unrelated field: the study of how volcanic glass dissolves and recrystallizes over geological time. In that world, scientists have worked out elegant mathematics describing how large crystals grow at the expense of small ones — a process called Ostwald ripening — and how competing processes of droplet formation versus crystal growth play out. The hypothesis proposes that the same competition happens inside a dissolving drug tablet. Specifically, it suggests that polymer molecules act like bouncers at a crystal's door: they stick preferentially to crystal surfaces (blocking growth) but leave liquid droplets of drug alone. This creates three distinct behavioral zones — regimes where droplets dominate, where crystals dominate, or where the two battle it out — all predictable by a single mathematical framework. The really clever part is the 'why': polymers are proposed to avoid liquid droplet surfaces because of a physics concept called conformational entropy — basically, a long floppy polymer molecule loses freedom of movement when it tries to coat a soft, wobbly liquid surface, so it doesn't bother. But a rigid crystal surface? That's a different story. If this selective sticking mechanism is correct, it would explain why some polymer-drug combinations work beautifully while others fail unpredictably.

This is an AI-generated summary. Read the full mechanism below for technical detail.

Why This Matters

If confirmed, this framework could give pharmaceutical chemists a predictive tool for designing amorphous solid dispersions — the formulation strategy behind dozens of blockbuster drugs including treatments for HIV and cancer — rather than relying on expensive trial-and-error. It could help identify which polymers are best suited to stabilize specific drugs, potentially cutting years off drug development timelines. The model might also explain puzzling cases where a drug formulation works well in lab tests but fails in patients, pointing toward better in vitro testing methods. Given that roughly 90% of drug candidates in development have poor solubility, even a modest improvement in predictive power here could have enormous downstream consequences for which medicines actually reach patients.

M

Mechanism

Polymer molecules preferentially adsorb to crystalline nuclei surfaces (via H-bonding to lattice planes) but not to LLPS droplet surfaces (due to conformational entropy penalty at liquid-liquid interface). This creates selective nucleation inhibition:

J_cryst = A_cryst exp(-DeltaG_cryst / kT) * (1 - I_polymer)

Three phase evolution regimes:

  1. LLPS-dominated (high polymer, low supersaturation)
  2. Competition zone (intermediate)
  3. Crystallization-dominated (low polymer, high supersaturation)
?

How to Test

  1. Time-resolved DLS + optical microscopy at varying polymer concentrations
  2. Measure k_ads via crystallization inhibition assays
  3. Effort: 6+ months, ~$50K
  4. NOTE: Overlap with H1.6-E; consider testing both frameworks simultaneously

Other hypotheses in this cluster

Dual Saturation Index Competition Predicts LLPS vs. Crystallization Pathway Switching in Ionizable Drug ASD Dissolution

CONDITIONAL
Volcanic glass dissolution kinetics
PHREEQC-style simultaneous SI computation for dual LLPS and crystallization p...
Pharmaceutical amorphous solid dispersion dissolution
Earth & Planetary ScienceHealth & Pharmacology

A geology-borrowed math trick could predict how experimental drugs behave in your stomach before they're ever tested.

8Score
5Confidence
7Grounded

TST Dissolution Kinetics in the Surface-Reaction-Limited Regime of Low Drug-Loading ASDs

CONDITIONAL
Volcanic glass dissolution kinetics
TST rate law with Damkohler criterion applied to drug-polymer H-bond disrupti...
Pharmaceutical amorphous solid dispersion dissolution
Earth & Planetary ScienceHealth & Pharmacology

A volcano science equation could predict how poorly soluble drugs dissolve — and when they fail.

8Score
5Confidence
7Grounded

Grambow Rate Law 2 Predicts Competitive Passivation-Erosion Kinetics and Regime Switching in ASD Dissolution

CONDITIONAL
Volcanic glass dissolution kinetics
Nuclear waste glass Rate Law 2 competitive passivation-erosion ODE with repta...
Pharmaceutical amorphous solid dispersion dissolution
Earth & Planetary ScienceHealth & Pharmacology

A nuclear waste glass equation could predict how drug pills dissolve — and explain why polymer size changes everything.

8Score
5Confidence
7Grounded

Pressure-Fracture Competition Regime Map for ASD Manufacturing Optimization

CONDITIONAL
Volcanic glass dissolution kinetics
Geochemical activation volume pressure-dependent kinetics applied to ASD tabl...
Pharmaceutical amorphous solid dispersion dissolution
Earth & Planetary ScienceHealth & Pharmacology

A single number borrowed from volcano science could predict how pressure affects dissolving drug tablets.

6Score
5Confidence
5Grounded

Related hypotheses

Can you test this?

This hypothesis needs real scientists to validate or invalidate it. Both outcomes advance science.